Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

----------------

Cash provided by financing

activities - $10,150 $36 $18,042

-------------------------------------------------------------------------

Funds from (purchases of)

short-term investments (1,427) (8,286) 6,201 (11,097)

Proceeds on disposal of

equipment - - 12 -

Purchases of property and

equipment (147) (30) (331) (201)

-------------------------------------------------------------------------

Cash provided by (used in)

investing activities $(1,574) $(8,316) $5,882 $(11,298)

-------------------------------------------------------------------------

(Decrease) increase in

cash and cash equivalents $(4,022) $(342) $(1,081) $(797)

Cash and cash equivalents,

beginning of period 5,886 5,288 2,945 5,743

-------------------------------------------------------------------------

Cash and cash equivalents,

end of period $1,864 $4,946 $1,864 $4,946

-------------------------------------------------------------------------

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Addition
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 2015 Optimal Research, LLC has been nominated ... Award "Best Clinical Site or Trial Network". ... been selected as a nominee in this ViE award ... Recommended" distinction in 2014. The ViE awards were created ... and positive contributions of companies and individuals in the ...
(Date:3/25/2015)... 2015 Laboratory workers can turn ... Analytical Balances to get best-performing features while still ... balances from the trusted brand include: , ... your efficiency by providing a large weighing surface ... modes include parts counting, percent weighing, checkweighing, animal/dynamic ...
(Date:3/25/2015)... 2015 An increase of awareness related ... forms of food nutrients, regulatory changes and concerns related ... in demand for natural astaxanthin over the past few ... up their capacities to satisfy the rising demand. ... source astaxanthin (used in nutraceuticals, aqua feed, food and ...
(Date:3/25/2015)... 2015 Having added two International locations ... of 2014, ITRA Global proudly announced recently the organization’s ... Representative Alliance, based in the United States, is one ... occupiers of commercial real estate. , Saltwood International ... Poland that exclusively advises occupiers of office space, ensuring ...
Breaking Biology Technology:Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2International Organization Expands its Global Reach to Warsaw, Poland 2
... 25 Years of Life ... Sciences Industry Experience, RANCHO CORDOVA, Calif., Aug. ... innovative products that,process and store adult stem cells, said today that ... America, has been named to the Company,s Board of,Directors. Her appointment ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, will announce its second quarter 2008,financial and ... 12,2008. The Company will host a conference call ... day at 4:30 p.m., Eastern Time., Participants ...
... $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48, ... WPI ), a leading specialty pharmaceutical,company, today reported financial ... Second Quarter 2008 Results, Net revenue for the ... $60.3 million, or $0.53 per diluted share. Net income ...
Cached Biology Technology:ThermoGenesis Names Tiffany Olson to Board of Directors 2ThermoGenesis Names Tiffany Olson to Board of Directors 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 4Watson Pharmaceuticals Reports Second Quarter 2008 Results 5Watson Pharmaceuticals Reports Second Quarter 2008 Results 6Watson Pharmaceuticals Reports Second Quarter 2008 Results 7Watson Pharmaceuticals Reports Second Quarter 2008 Results 8Watson Pharmaceuticals Reports Second Quarter 2008 Results 9Watson Pharmaceuticals Reports Second Quarter 2008 Results 10Watson Pharmaceuticals Reports Second Quarter 2008 Results 11Watson Pharmaceuticals Reports Second Quarter 2008 Results 12Watson Pharmaceuticals Reports Second Quarter 2008 Results 13Watson Pharmaceuticals Reports Second Quarter 2008 Results 14Watson Pharmaceuticals Reports Second Quarter 2008 Results 15Watson Pharmaceuticals Reports Second Quarter 2008 Results 16Watson Pharmaceuticals Reports Second Quarter 2008 Results 17
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Consider that some strains of algae produce toxins ... harmful varieties suck oxygen out of water, suffocating living ... blooms in the Great Lakes, for instance, threaten critical ... and colleagues have figured out how to outsmart the ...
... function!" was the credo of early 20th century architects making ... Cell biologists may be turning that on its head. New ... Standards and Technology (NIST) reinforces the idea that stem cells ... solely by controlling their shape. The results may be important ...
... heart development may also play a part in colon cancer ... Center and the Vanderbilt Eye Institute suggests that the protein ... in regulating corneal cells may be a therapeutic target ... in the October issue of the Journal of Clinical ...
Cached Biology News:Outsmarting algae -- RIT scientist finds the turn-off switch 2Shaping up: Controlling a stem cell's form can determine its fate 2Protein found in heart may be target for colon cancer therapies 2Protein found in heart may be target for colon cancer therapies 3
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
...
... MS/MS analysis & ... identified across multiple samples. ... scores for increased confidence. ... accurate information from your ...
Biology Products: